Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet
Author: Baccarani, M.
Cortes, J.
Pane, F.
Niederwieser, D.
Saglio, G.
Apperley, J.
Cervantes, F.
Deininger, M.
Gratwohl, A.
Guilhot, F.
Hochhaus, A.
Horowitz, M.
Hughes, T.
Kantarjian, H.
Larson, R.
Radich, J.
Simonsson, B.
Silver, R.
Goldman, J.
Hehlmann, R.
Citation: Journal of Clinical Oncology, 2009; 27(35):6041-6051
Publisher: Amer Soc Clinical Oncology
Issue Date: 2009
ISSN: 0732-183X
Statement of
Michele Baccarani, Jorge Cortes, Fabrizio Pane, Dietger Niederwieser, Giuseppe Saglio, Jane Apperley, Francisco Cervantes, Michael Deininger, Alois Gratwohl, François Guilhot, Andreas Hochhaus, Mary Horowitz, Timothy Hughes, Hagop Kantarjian, Richard Larson, Jerald Radich, Bengt Simonsson, Richard T. Silver, John Goldman and Rudiger Hehlmann
Abstract: Purpose: To review and update the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia with imatinib and second-generation tyrosine kinase inhibitors (TKIs), including monitoring, response definition, and first- and second-line therapy. Methods: These recommendations are based on a critical and comprehensive review of the relevant papers up to February 2009 and the results of four consensus conferences held by the panel of experts appointed by ELN in 2008. Results: Cytogenetic monitoring was required at 3, 6, 12, and 18 months. Molecular monitoring was required every 3 months. On the basis of the degree and the timing of hematologic, cytogenetic, and molecular results, the response to first-line imatinib was defined as optimal, suboptimal, or failure, and the response to second-generation TKIs was defined as suboptimal or failure. Conclusion: Initial treatment was confirmed as imatinib 400 mg daily. Imatinib should be continued indefinitely in optimal responders. Suboptimal responders may continue on imatinb, at the same or higher dose, or may be eligible for investigational therapy with second-generation TKIs. In instances of imatinib failure, second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.
Keywords: European LeukemiaNet
Antineoplastic Agents
Protein Kinase Inhibitors
Drug Monitoring
Treatment Outcome
Treatment Failure
Hematopoietic Stem Cell Transplantation
Transplantation, Homologous
Drug Administration Schedule
Gene Expression Regulation, Leukemic
Time Factors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib Mesylate
Rights: © 2009 American Society of Clinical Oncology
DOI: 10.1200/JCO.2009.25.0779
Appears in Collections:Aurora harvest
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.